3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
50
Terminated
13
Unknown
2
Withdrawn
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
9
Lymphoid
7
Myeloid
6
Plasma cell
1
Classical hematology
1
Conditions
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hodgkin Disease
1
Interventions
Dexamethasone
98
daratumumab
57
Lenalidomide
53
Bortezomib
38
pomalidomide
37
Cyclophosphamide
37
carfilzomib
25
Calcium Dobesilate
25
fludarabine
22
talquetamab
19
iberdomide
18
isatuximab
17
Specimen Handling
17
Magnetic Resonance Spectroscopy
17
Biopsy
15
selinexor
13
dexamethasone acetate
12
belantamab mafodotin
12
Melphalan
12
dexamethasone 21-phosphate
11
auricularum
10
venetoclax
8
fludarabine phosphate
7
elotuzumab
7
X-Rays
6
tocilizumab
5
Blood Specimen Collection
5
ruxolitinib
4
ixazomib
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Cyclosporine
×
Plasma cell
×
Clear all
NCT04888741
2026-05-05
MoTD
University of Birmingham
Phase 2
Recruiting
400 enrolled